Icariin: from preclinical promise to clinical reality-a critical evidence-based assessment.

Authors

Chengjuan Gu, Yuan Lin, Zhaobo Wang, Mengtian Li, Lin Du, Xingrong Lai, Liping Qiao, Han Wang, Jia Wang, Xiaolin Tong

Published in

Frontiers in pharmacology. Volume 17. Pages 1832264. Epub Sep 16, 2026.

Abstract

Icariin (ICA), the principal flavonoid from Epimedii Folium, aligns with traditional Chinese medicine indications of tonifying kidney-yang and strengthening bone. Prior reviews mostly catalog ICA's preclinical neuroprotective, anti-fibrotic, anti-tumor, and osteoprotective effects, but lack evidence stratification. Here, we establish an evidence-stratified framework to evaluate ICA's structure-activity relationships, pharmacokinetics, and safety profiles, explicitly distinguishing preclinical pharmacological actions from unproven clinical efficacy. We delineate translational barriers including interspecies pharmacokinetic gaps, poor bioavailability, and flawed trial designs, and assess delivery systems to address these limitations. This work bridges traditional Chinese medicine practice with graded modern evidence, providing a translational roadmap to guide ICA's rational clinical development.

PMID:
42819598
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.